Clinical Effect of Bronchial Artery Perfusion with Albumin Paclitaxel+Lo-baplatin Chemotherapy Combined with Arterial Embolization for Ad-vanced Non-small Cell Lung Cancer
Objective To explore the clinical effect of advanced non-small cell lung cancer(NSCLC)patients treated with Nanoparticle Albumin Bound Paclitaxel(NAB-PTX)+lobaplatin(LBP)chemotherapy combined with arterial em-bolization.Methods A total of 40 patients with advanced NSCLC admitted to Caoxian People's Hospital from Febru-ary 2021 to October 2023 were selected as the study objects and were divided into a study group and a control group with 20 cases in each group by random number table method.Both groups were given arterial embolization treatment.The control group was given bronchial arterial infusion NAB-PTX+cisplatin(DDP)chemotherapy,and the study group was given bronchial arterial infusion NAB-PTX+LBP chemotherapy.Recent efficacy and serum tumor markers were compared between the two groups.Results The objective response rate was 65.00%in the study group,higher than 30.00%in the control group,the difference was statistically significant(χ2=4.912,P<0.05).The levels of carbohy-drate antigen 125 and carcinoembryonic antigen decreased in both groups after treatment,and were lower in the study group compared to the control group,the differences were statistically significant(all P<0.05).Conclusion Bronchial artery perfusion NAB-PTX+LBP chemotherapy combined with arterial embolization can improve clinical efficacy and reduce serum tumor marker levels when applied in the treatment of advanced NSCLC patients.
Bronchial artery perfusionAlbumin paclitaxelLobaplatinArterial embolizationAdvanced non-small cell lung cancer
NETL
NSTL
万方数据
